Homepage Top Section2

The breakthrough therapy designation allows the combination therapy as a first-line treatment for people with metastatic NSCLC whose tumours have high PD-L1 expression with no EGFR or ALK

Arvelle Therapeutics is involved in the development of advanced solutions to treat patients suffering from central nervous system (CNS) disorders. The company is currently engaged in the development

Under the terms of the proposed agreement, the company will commence distribution of the vaccine in the second quarter of 2021. The Moderna COVID-19 vaccine has not been

Expected to improve competition and access to more affordable medicines, the approval has been given to the first generic of glucagon for injection USP, 1 mg/vial packaged in

UB-612 is said to be the first multitope, synthetic peptide-based Covid-19 vaccine candidate. Under the terms of the deal, Aurobindo Pharma will leverage its existing development, commercial and

With the latest deal, the companies now will deliver up to 200 million doses to the US. Both firms plan to supply the full 200 million doses to

In July this year, the company revealed a potential two-pronged strategy for the treatment of Covid-19. First, preclinical cell culture experiments shown CRV431 reduced SARS-CoV-1 production of infectious

As per the EUA, the mRNA-1273 vaccine can be administered to individuals aged 18 years or older. Following the EUA, Moderna has commenced delivery of the Covid-19 vaccine

Lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), may lead to end-stage kidney disease. Benlysta, a BLyS-specific inhibitor, is a human monoclonal antibody